We selected the six markers [CDKN2A (p16), IGF2, MLH1, MINT1, MINT2, and MINT31] that were methylated in more than 5% of the rectal carcinoid tumors as CIMP markers. Here, CDKN2A is linked to rectal neuroendocrine tumor G1.